Ekso Bionics Holdings Inc (EKSO) FinancialsEKSOEkso Bionics Holdings Inc

Ekso Bionics Holdings Inc (EKSO) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Device sales, accounting for 75.6% of total sales, equivalent to $3.12M. Other significant revenue streams include Service, support and Parts and other. Understanding this composition is critical for investors evaluating how EKSO navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Ekso Bionics Holdings Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -212.27%, provide a clear picture of how effectively EKSO converts its operational activities into shareholder value.

In the context of the broader market, EKSO competes directly with industry leaders such as TELA and CTSO. With a market capitalization of N/A, it holds a significant position in the sector. When comparing efficiency, EKSO's gross margin of N/A stands against TELA's 69.17% and CTSO's 73.18%. Such benchmarking helps identify whether Ekso Bionics Holdings Inc is trading at a premium or discount relative to its financial performance.

Latest reported quarter: 2025/Q4. Revenue declined to 3.14M, down 38.31% YoY, which indicates shrinking top-line momentum. Net income was -4.674M, still negative, although the loss improved 36.95% YoY. EPS dropped to 0 and gross margin dropped to 0, both signaling poor operating quality and weak profitability. For a long-term beginner investor, these financials do not support an aggressive buy.